Hello, I am Dr. Hidenori Shimada of Grand Green Osaka Umekita Clinic in Osaka, Japan.
When you read about regenerative medicine, you will often see the word “autologous.” It simply means that the cells come from your own body. For international patients exploring adipose-derived stem cell therapy in Japan, understanding this one word helps you ask better questions before a consultation. This article explains what it means, what it does and does not tell you about a treatment, and what to prepare before speaking with a doctor at Grand Green Osaka Umekita Clinic.
The short answer: autologous means your own cells
In the treatment described by Grand Green Osaka Umekita Clinic, a very small amount of fat tissue is collected from the patient under local anesthesia. Mesenchymal stem cells contained in that tissue are cultured and expanded at a specialized facility, and the cells are later returned to the same person by intravenous infusion. Because the cells originate from the patient, the approach is called autologous.
This differs from allogeneic therapy, in which cells come from a donor. Donor-derived cells can raise additional questions about immune compatibility. With autologous cells, the risk of rejection or allergic reaction is generally considered lower, although that does not mean the risk is zero. Every medical procedure carries some uncertainty, and your own medical history matters.
Why fat tissue is used as the source
Mesenchymal stem cells are somatic stem cells found in several tissues, including bone marrow and fat. Fat tissue is reported to contain relatively abundant mesenchymal stem cells, and it can be collected through a small incision under local anesthesia. Only a few rice-grain-sized pieces are needed, which is generally a smaller physical burden than bone marrow collection.
Mesenchymal stem cells are also reported in the research literature to release anti-inflammatory substances and growth factors that may support the repair of damaged tissue. It is important to read such statements carefully. They describe findings from studies, and they do not promise that any individual patient will experience a particular result.
What autologous does not guarantee
It is easy to hear “using your own cells” and conclude that a treatment must be gentle or risk free. That would be a misunderstanding. Several points remain important even when cells are autologous.
- Fat collection and intravenous infusion are still medical procedures, and they can involve discomfort, bleeding, bruising, infection, or other adverse events.
- Culture quality depends on the processing facility, its controls, and the individual starting material.
- Evidence for regenerative medicine varies by condition, and many questions remain under study.
- The treatment does not replace standard medical care, and it should not be viewed as an alternative to it.
A responsible consultation should discuss both possible benefits and possible downsides, and should leave room for you to decide not to proceed.
How the Japanese system fits in
In Japan, regenerative medicine is provided under the Act on the Safety of Regenerative Medicine. Clinics offering this kind of treatment are required to submit a regenerative medicine provision plan, and cell processing is carried out at facilities that meet legal requirements. Grand Green Osaka Umekita Clinic states that its treatment is provided under this framework.
This treatment is offered as a self-pay service that is not covered by public health insurance. Fees, the number of sessions, risks, side effects, and whether the treatment is appropriate for you must all be confirmed through a medical consultation. Patients visiting from overseas should also check how their own insurer and home country treat such care, since rules differ.
Questions to bring to your consultation
Preparing a short list makes the most of a consultation, especially when you are communicating across languages. Consider asking the following.
- Are the cells strictly my own, and where are they cultured and checked?
- What are the known risks and side effects, and how are they managed afterward?
- What does the evidence say for my specific condition, and what is still uncertain?
- What will I need to do before and after treatment, and how long will the process take from collection to infusion?
- What are the total costs, and what is and is not included?
- How will follow-up work after I return to my home country?
Bring your medical records, a list of current medications, and any allergies. If your condition is being treated by a physician at home, tell the doctor in Osaka and consider informing your home physician as well.
Planning a visit from overseas
Grand Green Osaka Umekita Clinic is located in the Umeda area of Osaka and offers an information page for international patients in multiple languages. Because the process involves a fat collection visit, a culture period, and a later infusion visit, timing and travel should be discussed in advance. A clear schedule helps you avoid rushed decisions.
Autologous stem cell therapy is one option to understand, not a decision to make quickly. Taking time to read, to ask questions, and to speak with a doctor will help you judge whether this approach fits your situation. If you would like to learn more, the clinic’s treatment page and consultation channels are the best starting point.
- Cells from your own fatCollected under local anesthesia
- Risks still existDiscuss side effects first
- Japanese legal framework
- Doctor consultation firstSelf-pay, confirm fees
This figure is a conceptual summary of the article content
References
- PubMed: Regenerative Capacity of Adipose Derived Stem Cells (ADSCs), Comparison with Mesenchymal Stem Cells (MSCs). (2019)
- PubMed: Comparison of allogeneic vs autologous bone marrow–derived mesenchymal stem cells delivered by transendocardial injection in patients with ischemic cardiomyopathy: the POSEIDON randomized trial. (2012)
- PubMed: Randomized Comparison of Allogeneic Versus Autologous Mesenchymal Stem Cells for Nonischemic Dilated Cardiomyopathy: POSEIDON-DCM Trial. (2017)
- PubMed: Intraarticular injection of bone marrow-derived mesenchymal stem cells enhances regeneration in knee osteoarthritis. (2020)
- PubMed: Allogeneic vs. autologous intra-articular mesenchymal stem cell injection within normal horses: Clinical and cytological comparisons suggest safety. (2020)
- PMC: Stem cell treatment for patients with autoimmune disease by systemic infusion of culture-expanded autologous adipose tissue derived mesenchymal stem cells. (2011)
- PMC: Treatment of faecal incontinence using allogeneic-adipose-derived mesenchymal stem cells: a study protocol for a pilot randomised controlled trial. (2016)
- PMC: Adipose-derived stem cells in the treatment of hepatobiliary diseases and sepsis. (2022)
- MHLW (Japan): Regenerative Medicine — Ministry of Health, Labour and Welfare, Japan
Supervising Physician
Director, Medical Corporation Shimada Clinic
Head of Clinical Practice, Grand Green Osaka Umekita Clinic
Hidenori Shimada
Graduated from the University of Tokushima Faculty of Medicine in 2005. After his initial residency, he obtained U.S. medical certification (ECFMG) and trained as a sub-intern in general surgery at the University of Washington. After completing the doctoral program at Kyoto University Graduate School of Medicine and working as a researcher at the Center for iPS Cell Research and Application (CiRA), Kyoto University, he founded Shimada Clinic in 2013. At Grand Green Osaka Umekita Clinic (https://umekitaclinic.org), he is engaged in a wide range of care, from internal medicine and pediatrics to cell therapy and aesthetic medicine.
* The physician supervision of this article covers its academic content only and does not constitute a recommendation of any specific treatment or product.